Tag: Sod1 als

In a combined analysis of the VALOR trial and its open-label extension, starting tofersen earlier slowed the decline in clinical function, respiratory function, and muscle strength in SOD1-ALS patients compared to delayed initiation. This critical finding helps clarify **how effective is tofersen** beyond the initial trial results.

According to manufacturer Biogen, the wholesale acquisition cost for a single vial of Qalsody (tofersen) is $14,230. This puts the first-year list price for tofersen at nearly $200,000, creating significant discussion around the cost of this rare disease treatment.